What NCT05936151 measured first
| Placebon=58 | Retatrutiden=55 |
|---|---|
| -0.19(2.690) | -1.62(2.820) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
Last updated
A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24 (mL/min/1.73 m²), Baseline, Week 24. Placebo: -0.19; Retatrutide: -1.62.
As posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
| Placebon=58 | Retatrutiden=55 |
|---|---|
| -0.19(2.690) | -1.62(2.820) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
Percent of participants affected, Baseline up to end of follow-up (up to 28 weeks). The most common events the registry lists.
| Event | Placebo | Retatrutide |
|---|---|---|
| Any serious event | 8.7% | 12.3% |
| Diarrhoea | 5.8% | 13.7% |
| Nausea | 5.8% | 9.6% |
| Decreased appetite | 0% | 8.2% |
| Gastrooesophageal reflux disease | 0% | 5.5% |
| Hypotension | 4.3% | 5.5% |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=58 | Retatrutiden=55 |
|---|---|
| -4.08(1.923) | -4.34(1.993) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=19 | Retatrutiden=23 |
|---|---|
| -8.75(17.575) | -53.65(8.267) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=61 | Retatrutiden=55 |
|---|---|
| 0.06(0.075) | -0.23(0.082) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=55 | Retatrutiden=53 |
|---|---|
| -0.01(0.008) | -0.02(0.008) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=60 | Retatrutiden=62 |
|---|---|
| 0.6(22.37) | -6.9(22.25) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=59 | Retatrutiden=62 |
|---|---|
| 0.02(0.008) | -0.02(0.008) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=59 | Retatrutiden=62 |
|---|---|
| 1.12(1.790) | -2.12(1.762) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=59 | Retatrutiden=62 |
|---|---|
| -0.58(0.442) | 0.33(0.436) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=62 | Retatrutiden=59 |
|---|---|
| 0.19(1.016) | -5.95(1.053) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=61 | Retatrutiden=58 |
|---|---|
| 0.40(1.162) | -8.38(1.206) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=59 | Retatrutiden=58 |
|---|---|
| 2.58(2.971) | 8.09(3.033) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
| Placebon=59 | Retatrutiden=58 |
|---|---|
| 0.56(0.481) | 2.82(0.494) |
From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Inclusion Criteria: * Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²) * Have either * no T2D with an HbA1c \< 6.5% or * have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening. * Have been diagnosed with chronic kidney disease (CKD). Exclusion Criteria: * Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening. * Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin * Have a prior or planned surgical treatment for obesity * Have Type 1 Diabetes (T1D) * Have acute or chronic hepatitis * Have a history of malignant disease within 5 years before screening.
In the trial's own words, from its record on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.